Literature DB >> 1713814

In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.

R K Puri1, P Leland.   

Abstract

Interferon-alpha (IFN-alpha) has been shown to synergize with IL-2 in the regression of a variety of established murine tumours and studies are underway to explore this combination in patients with advanced cancers as well. To understand the mechanism of synergy we have studied lymphokine-activated killer (LAK) cell activity in various compartments of mice in response to IFN-alpha and IL-2 administration. The effects of IFN-gamma, TNF-alpha and IL-4 were also examined. C57BL/6 mice were injected intraperitoneally with HBSS, IL-2 alone, IFN-alpha alone or both, two times a day for 7 days. On days 4 and 8, LAK activity was tested in a 4-h chromium release in cells obtained from lungs, spleen, and liver using fresh MCA-102 tumour cells as targets. The cells from control mice failed to lyse the MCA-102 target. IL-2 caused the generation of LAK activity and an increase in total cell yield in all the organs after 3 days of injection. IFN-alpha failed to generate LAK activity but when administered along with IL-2, caused synergistic enhancement of LAK lysis of MCA-102 target cells. Cell yield in this group was lower as compared with the IL-2-treated group. LAK activity tested after 7 days of IL-2 therapy was significantly decreased compared with that observed after 3 days. However, activity remained at as high a level after 7 days of therapy as after 3 days of therapy in animals treated with IFN-alpha and IL-2. FACS analysis revealed that asialo GM-1+ (ASGM-1) and NK1.1+ cells were increased in number in IL-2 and IL-2 plus IFN-alpha-treated spleen; however, the number of these cells was similar in both groups. In the liver, ASGM-1+ cells were higher in the IL-2 plus IFN-alpha group than in the group treated with IL-2 alone. By in vitro depletion utilizing antibody and Rbc' experiments, it was clear that both ASGM-1+ and NK1.1+ cells from the spleen mediated most of the cytotoxicity of MCA-102 targets. Pre-treatment irradiation (5 Gy) of mice completely abrogated the capability of IL-2 or IL-2 plus IFN-alpha to generate LAK activity. IFN-gamma also had a stimulatory effect on IL-2 induction of LAK activity. Tumour necrosis factor-alpha (TNF-alpha) and IL-4 failed to generate LAK activity and, in combination with IL-2, no additional stimulatory effect was observed.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713814      PMCID: PMC1535732          DOI: 10.1111/j.1365-2249.1991.tb05726.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Flow cytometric analysis reveals the presence of asialo GM1 on the surface membrane of alloimmune cytotoxic T lymphocytes.

Authors:  J Suttles; G A Schwarting; R D Stout
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

2.  Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes.

Authors:  P Lindahl; P Leary; I Gresser
Journal:  Proc Natl Acad Sci U S A       Date:  1972-03       Impact factor: 11.205

3.  Induction of major histocompatibility class I antigens by interferons in undifferentiated F9 cells.

Authors:  Y J Wan; B M Orrison; R Lieberman; P Lazarovici; K Ozato
Journal:  J Cell Physiol       Date:  1987-02       Impact factor: 6.384

4.  Antigen(s)-specific tumour-infiltrating lymphocytes from tumour induced by human herpes virus-6 (HHV-6) DNA transfected NIH 3T3 transformants.

Authors:  R K Puri; P Leland; A Razzaque
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

5.  Natural cell-mediated cytotoxicity in rats. II. In vivo augmentation of NK-cell activity.

Authors:  J R Oehler; L R Lindsay; M E Nunn; H T Holden; R B Herberman
Journal:  Int J Cancer       Date:  1978-02-15       Impact factor: 7.396

6.  Differential effects of recombinant interferons alpha, beta, and gamma on induction of human lymphokine (IL-2)-activated killer activity.

Authors:  S Sone; T Utsugi; A Nii; T Ogura
Journal:  J Natl Cancer Inst       Date:  1988-05-18       Impact factor: 13.506

7.  Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

Authors:  S A Rosenberg; M T Lotze; J C Yang; W M Linehan; C Seipp; S Calabro; S E Karp; R M Sherry; S Steinberg; D E White
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

8.  Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.

Authors:  J C Yang; J J Mulé; S A Rosenberg
Journal:  J Immunol       Date:  1986-07-15       Impact factor: 5.422

9.  Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma.

Authors:  S Silagi; R Dutkowski; A Schaefer
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

10.  Identification of a cell-surface antigen selectively expressed on the natural killer cell.

Authors:  L Glimcher; F W Shen; H Cantor
Journal:  J Exp Med       Date:  1977-01-01       Impact factor: 14.307

View more
  3 in total

1.  Potentiation of the therapeutic index of interleukin-2 immunotherapy by combination with taurine in a syngeneic murine tumour model.

Authors:  N Finnegan; D Toomey; C Condron; H P Redmond; M Da Costa; D J Bouchier-Hayes
Journal:  Ir J Med Sci       Date:  2002 Apr-Jun       Impact factor: 1.568

Review 2.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

3.  Natural-killer-stimulatory effect of combined low-dose interleukin-2 and interferon beta in hairy-cell leukemia patients.

Authors:  A M Liberati; V De Angelis; M Fizzotti; M Schippa; M Cecchini; D Adiuto; F Di Clemente; L Palmisano; E Micozzi; M Zuccaccia
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.